US-REGISTERED COMPANY
Skip to product information
Peptiva peptides
Research Compound Bremelanotide (PT-141)
€38,25
Sale price
€38,25
Regular price
€45,00
FOR IN VITRO LABORATORY RESEARCH ONLY.
Not intended for personal, clinical, diagnostic or veterinary use, or for administration to humans or animals.
Laboratory dispenser format
This description applies to the dispenser-format variant, not the vial-format variant.
The dispenser is a laboratory packaging and material-dispensing format. Product identity, declared quantity and storage conditions are stated in the specification for the individual material.
Laboratory dispensing format. It is not an injection or medical device and is not intended for administration to humans or animals.
MAIN RESEARCH AREAS Research profile
Editorial map of the main themes found in the scientific literature. Bar length is not a statistical score, efficacy rating, or indication for human use.
Description and specifications
Research Compound Bremelanotide (PT-141) is a laboratory material for analytical and in vitro work, available in a 10 mg variant.
What is bremelanotide?
Bremelanotide is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of approximately 1025 Da. It is structurally almost identical to Melanotan 2, differing only by a free carboxyl group at the C-terminus instead of an amide.
Research background
Bremelanotide emerged from the line of melanocortin analogue research begun at the University of Arizona and was later developed by Palatin Technologies. A regulated pharmaceutical preparation is approved for a narrowly defined indication and has its own documentation.
Mechanism and scientific context
Bremelanotide is a melanocortin receptor agonist with prominent activity at MC4R, a receptor expressed in the central nervous system. The small structural difference from Melanotan 2 is enough for the two molecules' profiles to be studied separately, making them an interesting pair for structure–selectivity research.
Main research areas
- MC4R and melanocortin receptors
- receptor selectivity
- structure–activity relationships of cyclic peptides
- central neuroendocrine signalling
Level of evidence
Clinical data exist for the approved pharmaceutical preparation. They cannot be attributed to this research material.
Research use only: for laboratory, analytical and in vitro research only; not for use in humans or animals. Not a medicine. Guidance on batch documentation is available in our COA guide.
PEPTIVA PRO E-BOOK · DIGITAL EDITION
Explore the scientific context in greater depth
The expanded guide covers more than 50 compounds, mechanisms of action, levels of evidence, limitations of the available data and research regimens reported in publicly available scientific literature.
- 50+ compounds covered in detail
- Preclinical and clinical data clearly distinguished
- Experimental approaches described in scientific literature
- COA, purity and documentation
Educational content is not medical advice, a recommendation for self-administration or instructions for using products sold in this store.
COA on request
To enquire about a certificate of analysis (COA), send the material name, requested variant and LOT / batch number if available. Documents are not published on this page.
Request a COA by emailThe button opens your email app with a prepared enquiry. You send the message yourself. peptivapeptides@protonmail.com
A COA applies to a specific batch and documents the analytical parameters tested for that batch. The product is intended strictly for laboratory, analytical and in vitro research.